Fate Therapeutics Inc FATE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.50
- Day Range
- $3.55–3.71
- 52-Week Range
- $1.63–8.83
- Bid/Ask
- $3.42 / $3.66
- Market Cap
- $405.41 Mil
- Volume/Avg
- 772,780 / 1.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 29.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 181
- Website
- https://www.fatetherapeutics.com
Comparables
Valuation
|
Metric
|
FATE
|
VRDN
|
ARVN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.00 | 4.47 | 2.78 |
Price/Sales | 29.54 | 4,373.22 | 11.55 |
Price/Cash Flow | — | — | — |
Price/Earnings
FATE
VRDN
ARVN
Financial Strength
|
Metric
|
FATE
|
VRDN
|
ARVN
|
|---|---|---|---|
Quick Ratio | 8.79 | 15.54 | 3.57 |
Current Ratio | 9.18 | 15.82 | 3.62 |
Interest Coverage | — | −92.88 | — |
Quick Ratio
FATE
VRDN
ARVN
Profitability
|
Metric
|
FATE
|
VRDN
|
ARVN
|
|---|---|---|---|
Return on Assets (Normalized) | −24.79% | −34.35% | −22.33% |
Return on Equity (Normalized) | −33.35% | −64.16% | −47.53% |
Return on Invested Capital (Normalized) | −30.13% | −41.62% | −54.26% |
Return on Assets
FATE
VRDN
ARVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Mtcblkmt | Fxdn | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vjpjqnzp | Vbxdmv | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pqvjglx | Wfymcm | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jxrfhcc | Tzzdgz | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Fyrkzrvb | Rqwck | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Fddfpddh | Fpx | $28.0 Bil | |||
| Moderna Inc
MRNA
| Smqfzsdp | Jbb | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Dspbpxmt | Sfcyc | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yhsjczxt | Zbyswq | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Dlknbwrk | Lxzsxrh | $12.6 Bil |
United States